Background: advanced-stage non-small cell lung cancer (NSCLC) is characterized by
having limited treatment options and thus a poor prognosis. However, new treatment …

Protein tyrosine phosphorylation is a crucial signaling mechanism that plays a role in
epithelial carcinogenesis. Protein tyrosine kinases (PTKs) control various cellular processes …

Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …

Objectives Mutations in the gene that encodes epidermal growth factor receptor (EGFR) are
biomarkers that predict how non-small cell lung cancer (NSCLC) patients respond to EGFR …

Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR) are becoming the
standard treatment option for patients with advanced non-small cell lung cancer (NSCLC) …

Background Epidermal growth factor receptor (EGFR) mutation is the most frequent mutation
tested in lung cancer for targeted therapy in the era of personalized medicine. Knowledge …

Background Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …

Simple Summary Evidence from randomized controlled trials about the efficacy of
monotherapy of afatinib on survival of patients with advanced non-small cell lung cancer …

Background Standard therapy of advanced non–small-cell lung cancer harboring an
activating mutation in the epidermal growth factor receptor (EGFR) gene is treatment with …

The Testin gene was previously identified in the fragile chromosomal region FRA7G at 7q31.
2. It has been implicated in several types of cancers including prostate, ovarian, breast and …